Oxytocin is a medication that is often used to strengthen contractions to overcome delayed labor progress. The primary aim of this study is to determine whether receiving a higher dose of oxytocin lowers the chance of needing a cesarean section when compared to a lower dose of oxytocin. Other aims include examining the relationship between dose of oxytocin regimen and length of labor, postpartum hemorrhage, intrauterine infection, umbilical cord gas, neonatal Apgar score \<5 at 5 minutes, and need for neonatal intensive care.
This randomized double blind clinical trial of consenting nulliparous women in spontaneous labor who require oxytocin for labor augmentation seeks to determine whether use of a high dose oxytocin regimen improves obstetric outcomes when compared with a low dose oxytocin regimen, in a manner that is safe for both mother and neonate. This project will include 1002 women recruited from the obstetrical service at Prentice Women's Hospital. Women will be included if they are at least 36 weeks gestation, have a singleton pregnancy, and have been diagnosed with spontaneous labor or spontaneous rupture of membranes. Women will be exposed to oxytocin for the indication of labor augmentation at the discretion of their obstetric provider. Women will be randomized with equal probability to intervention group using a fixed allocation procedure. To maintain a double blind design, the Prentice Women's Hospital pharmacy will carry out the randomization of oxytocin solutions according to the random assignment so that neither the women or their care providers nor the investigators will know the identity of the intervention assignment. The low-dose oxytocin regimen group will receive a starting oxytocin regimen concentration rate of 2 milliunits/minute that can be increased at increments of 2 milliunits/minute, as per the discretion of their obstetric provider. The high-dose oxytocin regimen group will receive a starting oxytocin regimen concentration rate of 6 milliunits/minute that can be increased at increments of 6 milliunits/minute, as per the discretion of their obstetric provider. Once the women are enrolled, randomized, and in receipt of their assigned interventions, further clinical management will be left to the discretion of each woman's obstetric provider. Prior to discharge from the hospital, baseline demographic and clinical data will be obtained via chart review.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
1,003
Northwestern Memorial Hospital
Chicago, Illinois, United States
Number of Participants Delivered by Cesarean
Number of participants delivered by cesarean section
Time frame: At time of delivery
Labor Augmentation Duration
Time from randomization to delivery
Time frame: Number of hours from randomization to delivery
Number of Participants With Postpartum Hemorrhage
Estimated blood loss greater than 500 milliliters after a vaginal delivery or greater than 1000 milliliters after a cesarean delivery
Time frame: From date of delivery to date of hospital discharge, an expected average of 3 days
Number of Participants With Intrapartum Chorioamnionitis
Fever greater than 100.4 Fahrenheit in the intrapartum period with the initiation of a therapeutic antibiotic regimen in the intrapartum period
Time frame: From time of labor admission to time of delivery, an expected average of 24 to 48 hours
Number of Participants With Postpartum Endometritis
Fever greater than 100.4 Fahrenheit in the postpartum period with the initiation of a therapeutic antibiotic regimen in the postpartum period
Time frame: From time of delivery to time of hospital discharge, an expected average of 3 days
Number of Participants Whose Offspring Experiences a Perinatal Death
Perinatal death includes intrapartum stillbirth and neonatal death
Time frame: Study enrollment to delivery (if intrapartum stillbirth) or 28 days of life (if liveborn)
Number of Participants With Umbilical Cord Acidemia
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Umbilical cord arterial blood pH less than 7.0 or base deficit greater than 12 mmol/L; or cord venous blood pH less than 7.0 or base deficit greater than 12 mmol/L when umbilical artery values are not available
Time frame: At time of delivery
Neonatal Apgar Score of Less Than 3 at 5 Minutes of Life
Number of participants with neonates with Apgar score of less than 3 at 5 minutes of life. This is using a Apgar scale which ranges from minimum total score of 0 and maximum total score of 10, with higher score representing a better outcome.
Time frame: Delivery through 5 minutes of life
Admission to Neonatal Intensive Care Unit
Number of participants whose neonates are admitted to Neonatal Intensive Care Unit
Time frame: Delivery to 28 days of life
Number of Participants Whose Neonates Experience a Composite of Severe Neonatal Morbidity and Perinatal Mortality
Neonatal composite morbidity will be defined as occurrence of any of the following: perinatal death, severe, respiratory distress, major birth injury, encephalopathy, seizure, need for hypothermic treatment, or sepsis
Time frame: Delivery to 28 days of life